...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Sciences >Genetic Analysis of HIV-1 Integrase Sequences from Treatment Naive Individuals in Northeastern South Africa
【24h】

Genetic Analysis of HIV-1 Integrase Sequences from Treatment Naive Individuals in Northeastern South Africa

机译：南非东北部幼稚个体HIV-1整合酶序列的遗传分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Raltegravir, an integrase inhibitor, is not a component of the current South African antiretroviral treatment guidelines, but it could be introduced in the near future as cases of virological failures from current treatment regimens begin to occur. The aim of this study was to analyze the complete HIV integrase gene obtained from individuals at two treatment sites in northeastern South Africa for the presence of Raltegravir associated drug resistant mutations and viral subtypes based on the integrase gene. Examination for mutations against other integrase inhibitors, such as Elvitegravir and Dolutegravir, was also done. Viruses from 127 treatment naive individuals were analyzed. Genetic drug resistance mutations were determined using the Stanford HIV Drug Resistance Interpretation program and the International AIDS society-USA guidelines. Viral subtyping was done by phylogenetic analysis, and recombinants were determined using the REGA, jpHMM and RIP tools. No major resistance mutations were detected. However, 7% of the sequences had minor mutations and polymorphisms. The majority (99%) of the viruses were HIV-1 C. Recombination analysis showed that the polymerase gene of one virus was likely composed of HIV-1 subtype A1 and C sequences. The present study indicates that Raltegravir, Elvitegravir and Dolutegravir resistant mutations may be absent in the study communities and further indicates the presence of recombinant viruses in northeastern South Africa.
机译：Raltegravir是整合酶抑制剂，不是当前南非抗逆转录病毒治疗指南的组成部分，但是随着当前治疗方案的病毒学失败病例的发生，它可能会在不久的将来引入。这项研究的目的是分析从南非东北部两个治疗地点的个体获得的完整的HIV整合酶基因，其中存在与Raltegravir相关的耐药突变和基于整合酶基因的病毒亚型。还针对其他整合酶抑制剂（例如Elvitegravir和Dolutegravir）的突变进行了检查。分析了来自127个未接受过治疗的个体的病毒。使用Stanford HIV耐药性解释程序和国际AIDS Society-USA指南确定了遗传耐药性突变。通过系统发育分析进行病毒亚型分析，并使用REGA，jpHMM和RIP工具确定重组子。没有检测到主要的抗药性突变。但是，有7％的序列具有较小的突变和多态性。大部分病毒（99％）是HIV-1C。重组分析表明，一种病毒的聚合酶基因可能由HIV-1亚型A1和C序列组成。本研究表明在研究社区中可能不存在Raltegravir，Elvitegravir和Dolutegravir耐药性突变，并且进一步表明在南非东北部存在重组病毒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号